Biotechnology company Valo Health Inc. and Merck KGaA announced on Thursday a collaboration on developing treatments for Parkinson’s disease and related disorders. The deal includes upfront and potential milestone payments to Valo of up to $3 billion in total.
Valo uses artificial intelligence, a database of over 17 million de-identified patient records and samples and a closed-loop chemistry platform to identify disease patterns and therapy targets and "rapidly develop and optimize small molecules" for treatment. "Valo Health’s AI‑enabled platforms utilizing human data will help sharpen target selection and streamline drug discovery, enabling us to advance the most promising candidates faster," Merck Global Head of Neurology & Immunology Research Unit Amy Kao said.
https://breakingthenews.net/Article/Valo-Health-partners-with-Merck-in-dollar3-billion-deal/65223383
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.